Treatment/Recovery – drugs

Commissioning impact on drug treatment, 2017
This independent report by the ACMD investigates the impact of commissioning on drug treatment. It looks at: commissioning structures, contracting arrangements and the financial environment, the impact on recovery outcomes for individuals and communities | ACMD, UK

Charter for change, 2017, (PDF)
The Drugs, Alcohol & Justice Cross-Party Parliamentary Group provides an interface for professional providers of drug and alcohol treatment with parliamentarians of all parties who share an interest in these issues. We seek to focus attention on addiction issues and advocate evidence-based policies, enabling treatment services to save and transform more lives | Drugs, Alcohol & Justice Cross-Party Parliamentary Group, UK

Guidance: Widening the availability of naloxone, 2017
Naloxone is the emergency antidote for overdoses caused by heroin and other opiates/opioids (such as methadone and morphine) | DoH et al, UK

Take-home naloxone for opioid overdose in people who use drugs (PDF), 2017
Advice for local authorities and local partners on widening the availability of naloxone to reduce overdose deaths from heroin and other opiate drugs | PHE, UK

Drug misuse and dependence: UK guidelines on clinical management, 2017
Often called the Orange Book, this is guidance for clinicians treating people with drug problems. This 2017 version offers new guidelines on:

  • prison-based treatment
  • new psychoactive substances and club drugs
  • mental health co-morbidity
  • misuse of prescribed and over-the-counter medicines
  • stopping smoking
  • preventing drug-related deaths, including naloxone provision

DoH, UK

Young people’s statistics from the National Drug Treatment Monitoring System (NDTMS): financial year ending March 2016, 2017
Results from the NDTMS on the number of young problem drug and alcohol users in contact with specialist treatment agencies and general practitioners between 1 April 2015 and 31 March 2016 | PHE, UK

Specialist substance misuse services for young people, 2017
Public Health England (PHE) commissioned The Children’s Society to undertake scoping research in early 2016, to understand some of the opportunities and challenges currently facing those now responsible for commissioning and delivering young people’s specialist substance misuse services and to outline some critical good practice principles | PHE, UK

An Independent Review into the impact on employment outcomes of drug or alcohol addiction, and obesity, 2016
The government asked Professor Dame Carol Black to undertake an independent review into how best to support people who are addicted to alcohol or drugs, or are obese, to start, return or remain in work. This review provides an evidence-based analysis of the factors that stand in the way of employment and recommends practical interventions to help overcome them | Secretary of State for Work and Pensions, UK

State of the Sector: Drug and Alcohol Family Support, 2016
Adfam has released a ground-breaking new report providing an overview into the state of the drug and alcohol family support sector. The field has seen a huge amount of change over the past few years, with dramatically reduced budgets, services being commissioned in different ways and changes to the way people use drugs and alcohol and the harm it causes to them and their families | Adfam, UK

European Drug Report 2016: Trends and Developments, 2016
What are the latest trends in drug supply to Europe? What drugs are causing the most harm and concern today? What are the most recent developments in drug prevention, treatment and policy? These and other questions are explored by the EMCDDA in its European Drug Report 2016 | EMCDDA, Portugal

Drug Treatment Matrix, 2016
The DrugTreatment Matrix maps the domain of treatment of problem drug use among adults and for each sub-domain (a cell) lists the most important UK-relevant research and guidance | Findings, UK

State of the Sector 2015, 2016
This report provides a third annual snapshot of a sector still in flux and faced by multiple challenges. The report finds: A continued trend of reduced funding reported by both community and residential services across the last three years; Funding changes reported as having a significant negative impact on the delivery of core services, workforce development and case-loads; Dual diagnosis remains a key challenge, with links with mental health services varying; Passion, innovation and resilience exist in many services across the country | Adfam and Recovery Partnership, UK

Club Drug Use Among Lesbian, Gay, Bisexual and Trans (LGBT) People (PDF), 2016
This report has been written as part of the wider suite of clinical guidance and tools that aim to provide evidence-based knowledge to inform the management in clinical practice of harms related to the use of ‘club drugs’. It is a supplement to, and should be read in conjunction with, Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances (www.neptune-clinical-guidance.co.uk) | Neptune Project, UK

Evaluation of Four Recovery Communities across England: Interim Report Summary, 2016 (PDF)
Since September 2014, Comic Relief has been working with the Centre for Public Health, Liverpool John Moores University, to find out how the recovery communities are contributing to ambitions of improved and sustained recovery. This report summarises the results | Centre for Public Health, Liverpool John Moores University, UK

Optimising opiate substitute therapy, 2015 (PDF)
In this report, the authors have have reviewed the evidence available on opiate substitution; provided detailed conclusions reached based on the evidence; and have detailed bespoke recommendations for Government, Local Authority Commissioners and Drug treatment services and staff | ACMD, UK

Treatment of cannabis-related disorders in Europe, 2015 (PDF)
This publication reviews the interventions used in the treatment of cannabis disorders and maps out the geography of cannabis treatment in Europe | EMCDDA, Portugal

Advice on time limited therapy, 2014 (PDF)
The overall conclusion of this report is that the evidence does not support the case for imposing a blanket time limit on OST treatment for heroin users, and this approach is not advised by the ACMD. As evidence strongly suggests that time limiting OST would result in the majority relapsing into heroin use and may have 2 significant unintended consequences including increasing: drug-driven crime (and national crime statistics); heroin overdose death rates; and, the spread of bloodborne viruses including hepatitis and HIV. Those implementing this approach could also face medico-legal challenges | ACMD, UK

Recovery-oriented methadone maintenance,  2010 (PDF)
There are growing calls to shift the acute-care model of addiction treatment to a model of sustained recovery support analogous to the long-term management of other chronic diseases. The purpose of this monograph is to explore what this shift means to the design and delivery of methadone maintenance (MM) treatment and the status of MM treatment and MM patients in the United States | William White and Lise Mojer-Tores, USA